Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
121-140 of 991 trials

Cutibacterium acnes Infections: Rifampicin Study

We are investigating whether rifampicin is safe and effective for treating prosthetic joint infections caused by Cutibacterium acnes. This study compares rifampicin with other antibiotic treatments to see which works better.

Joint Infection from Medical Devices>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Advanced Breast Cancer: Giredestrant vs. Fulvestrant

We are studying a new medication, giredestrant, to see if it works better than fulvestrant for patients with advanced breast cancer who have not responded to prior hormone therapy. The trial will also evaluate the safety of both treatments.

Estrogen Receptor Positive, HER2 Negative Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

ZN-c3 for High-Grade Serous Ovarian Cancer

We are studying a new treatment called azenosertib for individuals with high-grade serous ovarian cancer. The trial aims to evaluate its safety and effectiveness, especially in patients with a specific genetic marker.

Ovarian, Fallopian Tube, and Peritoneal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Atrial Fibrillation: Stopping Anticoagulants After Heart Surgery

We are studying whether patients with atrial fibrillation can safely stop anticoagulant therapy after undergoing surgical left atrial appendage closure. This trial looks at the risks of stroke and bleeding in these patients.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

Rheumatoid Arthritis: LY3871801 Study

We are testing a new medication, LY3871801, for adults with moderately-to-severely active rheumatoid arthritis. The study aims to see if it can reduce disease activity better than a placebo.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

TAK-330 for Reversing Blood Thinner Effects in Urgent Surgery

We are studying whether TAK-330 can effectively reverse the effects of certain blood thinners in patients needing urgent surgery. This trial compares TAK-330 to the standard treatment to see which works better.

Patients on Factor Xa Inhibitors Needing Urgent Intervention≤3 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Gastrointestinal Stromal Tumor: Ripretinib vs Sunitinib

We are comparing two treatments for advanced gastrointestinal stromal tumors in patients with specific genetic mutations who have been treated before. The goal is to find out which medication may help control the disease better and improve quality of life.

Advanced Gastrointestinal Stromal TumorConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Cystic Fibrosis: Vanzacaftor/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for cystic fibrosis in individuals aged one year and older. The trial aims to evaluate its long-term safety and effectiveness.

Cystic Fibrosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Limb Girdle Muscular Dystrophy 2E/R4: SRP-9003 Gene Therapy

We are studying a new gene therapy to see if it improves muscle function in people with Limb Girdle Muscular Dystrophy 2E/R4. The trial will evaluate its safety and effectiveness over time.

Limb-girdle Muscular Dystrophy Type 2E/R4>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Recurrent Solid Tumors: IMA402 Treatment Study

We are testing a new treatment called IMA402 for patients with recurrent or hard-to-treat solid tumors. The study aims to evaluate its safety and how well it works, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Melanoma: Lifileucel with Pembrolizumab

We are investigating whether a new treatment combining lifileucel with pembrolizumab is more effective than pembrolizumab alone for patients with untreated, advanced melanoma. The study aims to assess both effectiveness and safety.

MelanomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Mucopolysaccharidosis Type II: JR-141 Treatment Study

We are investigating the long-term effects of JR-141 on symptoms of Hunter Syndrome. This study will help us understand its safety and effectiveness for patients with this condition.

Mucopolysaccharidosis IIHunter Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurologyPediatrics

Alzheimer's Disease: PRI-002 Study

We are testing a new medication, PRI-002, for individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. The study aims to evaluate its safety and effectiveness in improving cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Fremanezumab for Pain in Complex Regional Pain Syndrome

We are studying whether fremanezumab can reduce pain in patients with Complex Regional Pain Syndrome compared to a placebo. The trial also examines how this treatment affects disease symptoms and function.

Complex Regional Pain Syndrome≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurology

ANCA-Associated Vasculitis: Avacopan Study

We are testing the long-term safety and effectiveness of Avacopan for people with ANCA-associated vasculitis. The study will also look at how it affects remission and overall quality of life.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineRheumatology

Vedolizumab for Kids with Ulcerative Colitis or Crohn’s Disease

We are studying a new injection form of Vedolizumab for children with moderate to severe ulcerative colitis or Crohn’s disease. The goal is to learn about its safety and how it works in the body after initial treatment.

Crohn's DiseaseUlcerative Colitis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Prostate Cancer: Long-Term Safety of Lutetium (177Lu) Treatment

We are investigating the long-term safety of lutetium (177Lu) vipivotide tetraxetan in adults with prostate cancer. This study aims to identify potential risks and serious side effects over time.

Prostate Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Systemic Sclerosis-Associated Lung Disease: Belimumab Study

We are testing whether belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis-related lung disease. This study compares its effects to a placebo alongside standard treatment.

Systemic Sclerosis Associated Interstitial Lung Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonologyRheumatology

Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

Atrial Fibrillation>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine